Every 8-K that Fulcrum Therapeutics, Inc. (FULC) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow FULC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full FULC filings page.
Fulcrum Therapeutics, Inc. is combining with Slate Medicines, Inc. in an all‑stock merger structured as a two‑step merger, after which Slate will be a wholly owned subsidiary and the combined company will focus on Slate’s migraine portfolio. The merger values Slate at $350.0 million and Fulcrum at $31.3 million for exchange‑ratio purposes and is intended to qualify as a tax‑free reorganization. On a fully diluted, pro forma basis including the concurrent financing, pre‑merger Slate stockholders are expected to own 55.9%, the new investors 39.1%, and pre‑merger Fulcrum stockholders 5.0% of the combined company, subject to net‑cash‑based adjustments. Slate has secured an oversubscribed private placement of approximately $245 million, and the combined company’s cash is expected to fund operations into 2029. Immediately prior to closing, Fulcrum expects to pay pre‑merger Fulcrum stockholders a cash dividend estimated at $270.0 million and contribute about $20.3 million in net cash to the combined entity. The combined company will be renamed Slate Medicines, Inc., is expected to trade on Nasdaq under “SLTE,” and will be led by Slate’s management team, with Slate designating all five board members. Closing is targeted for the fourth quarter of 2026, subject to shareholder approvals, HSR clearance, Nasdaq listing, effectiveness of a Form S‑4 registration statement, a reverse stock split, minimum net‑cash and completion of the private placement.
Fulcrum Therapeutics, Inc. reported an executive leadership change in its finance organization. Vice President, Finance and principal accounting officer Greg Tourangeau, whose planned departure had been previously disclosed, will end his tenure on August 7, 2026. Effective the same date, the Board appointed chief financial officer and principal financial officer Alan Musso to also serve as principal accounting officer.
Musso’s background is described in the company’s definitive proxy statement filed on April 30, 2026. He will not receive additional compensation for assuming the principal accounting officer role. The company states there is no arrangement or understanding with any person regarding his appointment, no family relationships with other directors or executive officers, and no related-party transactions involving Musso that require disclosure under Item 404(a) of Regulation S-K.
Fulcrum Therapeutics, Inc. reported the voting results from its 2026 annual meeting of stockholders held on June 24, 2026. Stockholders voted on the election of three director nominees and two additional proposals.
For the board seats, Sonja Banks received 43,187,717 votes for and 10,601,385 votes withheld, while Alan Ezekowitz received 52,317,282 votes for and 1,471,820 votes withheld. Colin Hill received 52,363,595 votes for and 1,425,507 votes withheld. Each director vote included 5,062,117 broker non-votes.
A separate proposal received 50,735,617 votes for, 3,026,397 votes against, 27,088 abstentions and 5,062,117 broker non-votes. Another proposal received 58,793,645 votes for, 36,178 votes against and 21,396 abstentions with no broker non-votes reported.
Fulcrum Therapeutics approved special retention and change-in-control protections for its remaining leadership after a major restructuring tied to ending development of pociredir for sickle cell disease. The compensation committee granted cash retention bonuses to nine remaining full-time employees, including top executives.
President and CEO Alex C. Sapir will receive $370,040, and Chief Legal Officer Curtis Oltmans and Chief Financial Officer Alan Musso will receive $195,480 and $195,200, respectively, payable in cash if there is a qualifying change in control or a termination without cause, subject to completion of transitional duties. Their employment agreements were amended to align retention payments with incremental change-in-control benefits.
The company also extended change-in-control benefits to remaining employees at the Vice President level and above on similar terms. Separately, Fulcrum disclosed that Vice President, Finance and principal accounting officer Greg Tourangeau will depart on a mutually agreed future date, and stated his departure is not due to any disagreement regarding financial reporting or controls.
Fulcrum Therapeutics is undertaking a major restructuring after discontinuing development of pociredir for sickle cell disease. The board approved a plan that cuts the workforce by about 85%, reducing headcount from 57 to 9 full-time employees, with the changes expected to be largely complete in the second quarter of 2026.
The company expects approximately $4.2 million in charges tied mainly to severance, benefits and related costs, most of which will require future cash payments during the same quarter. Fulcrum is also conducting a broad review of strategic alternatives and has hired Leerink Partners LLC to advise on potential transactions such as mergers, acquisitions, or asset sales, though there is no assurance that any deal will occur.
Fulcrum Therapeutics has discontinued development of pociredir, its lead program for sickle cell disease, after FDA feedback left no viable regulatory path forward. The FDA cited malignancy risks associated with PRC2 inhibition, referencing secondary hematologic cancers seen with the PRC2 inhibitor Tazverik, which was withdrawn globally in March 2026.
At the same time, Fulcrum has begun a comprehensive review of strategic alternatives, which may include a merger, acquisition, business combination, or other strategic transactions involving the company or its assets. The company is also taking steps to significantly reduce operating expenses and preserve capital. As of March 31, 2026, Fulcrum held $333.3 million in cash, cash equivalents, and marketable securities.
Fulcrum Therapeutics reported first quarter 2026 results and several corporate updates. The company ended the quarter with $333.3 million in cash, cash equivalents, and marketable securities and continues to expect its cash resources will fund operations into 2029. For the quarter ended March 31, 2026, Fulcrum recorded a net loss of $18.9 million, compared with $17.7 million a year earlier, as research and development expenses rose to $14.1 million and general and administrative expenses to $8.1 million.
Fulcrum highlighted positive Phase 1b PIONEER data for its lead sickle cell disease candidate pociredir, including robust fetal hemoglobin induction and improvements in markers of hemolysis and anemia, and plans a potential registration-enabling trial in the second half of 2026. The company also dosed the first patient in a long-term extension trial and maintained that pociredir has been generally well-tolerated with no treatment-related serious adverse events to date.
Strategically, Fulcrum terminated its July 2023 license agreement with CAMP4 Therapeutics covering a Diamond-Blackfan anemia program. Governance changes include appointing Josh Lehrer as an independent Class III director, with a stock option grant for 64,000 shares at $8.08 per share, and the planned retirement of chief financial officer Alan Musso, who will remain until a successor is named and then serve as a consultant to support an orderly transition.
Fulcrum Therapeutics reported a larger full-year 2025 net loss of $74.9 million, compared with $9.7 million in 2024, as it invested in its sickle cell disease program while collaboration revenue fell away. Cash, cash equivalents, and marketable securities rose to $352.3 million as of December 31, 2025, helped by $164.2 million of net proceeds from a December equity offering, giving projected cash runway into 2029.
Clinically, the company announced positive 12-week results from the 20 mg cohort (n=12) of its Phase 1b PIONEER trial of pociredir in sickle cell disease, with mean fetal hemoglobin increasing by 12.2% from 7.1% to 19.3% and improvements in markers of hemolysis and anemia. Pociredir was generally well tolerated with no treatment-related serious adverse events reported at the December 23, 2025 data cutoff. Fulcrum plans an open-label extension study and, pending FDA feedback, aims to start a potential registration-enabling trial in the second half of 2026 while discontinuing its bone marrow failure syndromes program.
Fulcrum Therapeutics, Inc. reported a preliminary estimate of approximately $352.3 million in cash, cash equivalents and marketable securities as of December 31, 2025. This figure is based on management’s estimates, is unaudited, and may change as year-end financial closing procedures are completed.
The company also released an updated corporate presentation with business and strategic updates, which it plans to use in investor meetings, including a presentation at the 44th Annual J.P. Morgan Healthcare Conference. The presentation is available via webcast and as an exhibit to this report.
Fulcrum Therapeutics, Inc. entered into an underwriting agreement for an underwritten public offering of 11,851,853 shares of common stock at $13.50 per share and pre-funded warrants to purchase up to 1,111,193 shares of common stock at $13.499 per warrant. The underwriters also have a 30-day option to buy up to 1,944,456 additional shares at the same price, less underwriting discounts and commissions.
All securities are being sold by Fulcrum, which expects to receive net proceeds of about $164.1 million, or about $188.1 million if the underwriters fully exercise their option, after fees and expenses. The pre-funded warrants have a $0.001 exercise price, are immediately exercisable, and include ownership limits generally capped at 19.99% of outstanding common stock and additional limits tied to Hart-Scott-Rodino antitrust thresholds.
The offering is being made under an effective shelf registration statement, with closing expected on or about December 11, 2025, subject to customary conditions. Fulcrum and its directors and executive officers have agreed to short lock-up periods restricting additional sales of common stock following pricing.
Fulcrum Therapeutics (FULC) filed an 8-K stating it announced financial results for the quarter ended September 30, 2025. A detailed press release was furnished as Exhibit 99.1 and incorporated by reference. The Item 2.02 information, including the exhibit, is furnished and not deemed filed under the Exchange Act. Fulcrum’s common stock trades on the Nasdaq Global Market under the symbol FULC.
Fulcrum Therapeutics, Inc. furnished an updated corporate presentation dated August 28, 2025 that may be used at conferences and investor meetings. The presentation is available in the Events and Presentations section of the company’s website and is attached as Exhibit 99.1. Fulcrum specifies that this material is provided under Regulation FD and is considered “furnished” rather than “filed,” which means it is not automatically subject to certain Exchange Act liabilities or incorporated into other securities law filings unless specifically referenced.
Fulcrum Therapeutics (NASDAQ:FULC) filed a Form 8-K reporting the results of its 26 June 2025 annual stockholder meeting.
- Shareholders elected Katina Dorton, Robert Gould and Kate Haviland as Class III directors for terms ending in 2028.
- The non-binding say-on-pay proposal passed with 46.1 million votes for, 0.11 million against and 8.3 thousand abstentions.
- Investors recommended an annual frequency for future say-on-pay votes (44.9 million votes for one year).
- Ernst & Young LLP was ratified as independent auditor for fiscal 2025 with 49.5 million votes for and no broker non-votes.
No other material corporate actions or operational changes were disclosed.